288 related articles for article (PubMed ID: 28525359)
1. I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.
Maseko SB; Padayachee E; Govender T; Sayed Y; Kruger G; Maguire GEM; Lin J
Biol Chem; 2017 Sep; 398(10):1109-1117. PubMed ID: 28525359
[TBL] [Abstract][Full Text] [Related]
2. Binding Free Energy Calculations of Nine FDA-approved Protease Inhibitors Against HIV-1 Subtype C I36T↑T Containing 100 Amino Acids Per Monomer.
Lockhat HA; Silva JR; Alves CN; Govender T; Lameira J; Maguire GE; Sayed Y; Kruger HG
Chem Biol Drug Des; 2016 Apr; 87(4):487-98. PubMed ID: 26613568
[TBL] [Abstract][Full Text] [Related]
3. Kinetic and thermodynamic characterisation of HIV-protease inhibitors against E35D↑G↑S mutant in the South African HIV-1 subtype C protease.
Maseko S; Padayachee E; Maphumulo S; Govender T; Sayed Y; Maguire G; Lin J; Naicker T; Baijnath S; Gerhardus KH
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1451-1456. PubMed ID: 31409143
[TBL] [Abstract][Full Text] [Related]
4. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
[TBL] [Abstract][Full Text] [Related]
5. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
6. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
7. An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.
Sanusi ZK; Govender T; Maguire GEM; Maseko SB; Lin J; Kruger HG; Honarparvar B
J Comput Aided Mol Des; 2018 Mar; 32(3):459-471. PubMed ID: 29397520
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
9. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
[TBL] [Abstract][Full Text] [Related]
10. Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study.
Mosebi S; Morris L; Dirr HW; Sayed Y
J Virol; 2008 Nov; 82(22):11476-9. PubMed ID: 18768960
[TBL] [Abstract][Full Text] [Related]
11. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
[TBL] [Abstract][Full Text] [Related]
12. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
13. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
14. Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies.
Maseko SB; Natarajan S; Sharma V; Bhattacharyya N; Govender T; Sayed Y; Maguire GE; Lin J; Kruger HG
Protein Expr Purif; 2016 Jun; 122():90-6. PubMed ID: 26917227
[TBL] [Abstract][Full Text] [Related]
15. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
16. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.
Velazquez-Campoy A; Muzammil S; Ohtaka H; Schön A; Vega S; Freire E
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):311-28. PubMed ID: 14754432
[TBL] [Abstract][Full Text] [Related]
17. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR.
Ahmed SM; Kruger HG; Govender T; Maguire GE; Sayed Y; Ibrahim MA; Naicker P; Soliman ME
Chem Biol Drug Des; 2013 Feb; 81(2):208-18. PubMed ID: 23017010
[TBL] [Abstract][Full Text] [Related]
19. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
Ahmed SM; Maguire GE; Kruger HG; Govender T
Chem Biol Drug Des; 2014 Apr; 83(4):472-81. PubMed ID: 24267738
[TBL] [Abstract][Full Text] [Related]
20. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]